Arcutis Biotherapeutics Highlights Results from the STRATUM Study of Zoryve (Roflumilast) Topical Foam, 0.3% for Seborrheic Dermatitis
Shots:
- The company highlighted the results from (STRATUM) study of Zoryve (QD, 8wks.) for treating adult (n=189) patients and adolescents (9yrs. and older) with moderate-to-severe seborrheic dermatitis contraindicated, intolerant, or unresponsive to topical steroids
- The results revealed 3.5 times more success in IGA with Zoryve vs vehicle (78.8% vs 48.3%). The QoL in patients of 17yrs. and older, assessed by DLQI, was improved at wks2, 4, and 8, with an odds ratio of 6.97. 72.5% attained a difference in DLQI score by 2wks., increasing to 86.6% at the study's end (28.1% and 53.6% for vehicle)
- Zoryve foam (QD) is a steroid-free topical suitable for all hair and skin types indicated for clearing and controlling seborrheic dermatitis. It is also being assessed for atopic dermatitis and approved for plaque psoriasis
Ref: Arcutis | Image: Arcutis
Related News:- Arcutis Biotherapeutics Reports Results for Zoryve Cream in P-II Trials for the Treatment of Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
